Financial Performance - Karyopharm Therapeutics reported quarterly losses of $2.77 per share, which was better than the analyst consensus estimate of losses of $4.16 per share [1] - The company reported quarterly sales of $30.02 million, missing the analyst consensus estimate of $35.24 million [1] Clinical Trial Update - The Phase 3 SENTRY trial in patients with JAKi-naïve myelofibrosis has passed its pre-specified futility analysis and continues as planned without modifications [2] - New data in hard-to-treat myelofibrosis patients showed spleen volume reduction, symptom improvement, hemoglobin stabilization, and evidence of disease modification with selinexor monotherapy [2] Sales Guidance and Market Reaction - Karyopharm affirmed FY2025 sales guidance of $140.00 million to $155.00 million, compared to market estimates of $149.32 million [3] - Following the earnings announcement, Karyopharm shares fell 15.6% to trade at $5.17 [3] Analyst Ratings and Price Targets - Baird analyst Michael Ulz maintained an Outperform rating and lowered the price target from $54 to $42 [8] - Barclays analyst Peter Lawson maintained an Overweight rating and raised the price target from $5 to $10 [8] - RBC Capital analyst Brian Abrahams maintained an Outperform rating and lowered the price target from $34 to $33 [8]

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $30 million, down from $33.1 million in Q1 2024 [46] - U.S. XPOVIO net product revenue decreased to $21.1 million from $26 million year-over-year, attributed to a $5 million increase in product return reserves [47] - Gross to net provisions for XPOVIO were 45% in Q1 2025 compared to 29.3% in the same period in 2024 [47] - Cash, cash equivalents, and investments at the end of Q1 2025 were $70.3 million, down from $109.1 million at the end of 2024 [48] Business Line Data and Key Metrics Changes - Demand growth for Q1 was 5% year-over-year, with net product revenue impacted by atypical returns of expired products [40] - Royalty revenue increased by 57% to $1.7 million in Q1 2025 compared to Q1 2024, reflecting growing global demand for XPOVIO [42] Market Data and Key Metrics Changes - The multiple myeloma market remains highly competitive, with expectations of additional new entrants this year [41] - The company anticipates a peak revenue potential of approximately $1 billion in the U.S. for selinexor in myelofibrosis if approved [10] Company Strategy and Development Direction - The company is focused on completing enrollment in the Phase III SENTRY trial for myelofibrosis and advancing the Phase III trial in endometrial cancer [7][38] - The strategy includes leveraging a profitable commercial organization in multiple myeloma to drive rapid commercialization in new disease areas [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of selinexor to redefine the standard of care in myelofibrosis, with encouraging clinical data supporting its efficacy [8][10] - The company is exploring various opportunities to extend its cash runway while focusing on advancing clinical trials and commercial performance [51][53] Other Important Information - The Phase III SENTRY trial successfully passed its pre-specified futility analysis, allowing the study to continue as planned [35] - The company expects to complete enrollment in the SENTRY trial by June-July 2025 [35][67] Q&A Session Summary Question: Can you talk about the futility analysis and its basis? - The futility analysis was based on efficacy and safety data from the first 61 patients, with thresholds for no worsening compared to ruxolitinib alone [55][56] Question: What are the assumptions for achieving full enrollment in June and July? - The company is currently 80% enrolled and expects to complete enrollment in the June-July timeframe, with a press release to follow [67] Question: What is driving utilization in multiple myeloma? - The company reported 5% growth in demand, with utilization driven by its flexible combination therapy positioning in both community and academic settings [82] Question: What is the normal run rate of return product? - The atypical returns of $5 million were related to high-dose products, and the company does not expect this to continue into future quarters [89] Question: How confident is the company in reaching its revenue guidance? - The company believes it can deliver at the lower end of its revenue guidance due to strong demand growth and global partner revenue [97]

Financial Data and Key Metrics Changes - The company ended the first quarter with a cash position of $204.1 million, which includes approximately $65.5 million in net proceeds from a public offering closed in January 2025 [23] - Total operating expenses for the quarter were $37.8 million, down 82% from the same period in 2024 [25] - Research and development expenses were $22.1 million compared to $36.6 million in Q1 2024, primarily due to decreased spending on AMX-thirty five and reductions in payroll and personnel costs [25] - Selling, general and administrative expenses were $15.7 million compared to $57.8 million in Q1 2024, mainly due to decreased payroll and consulting costs [25] Business Line Data and Key Metrics Changes - The company is advancing three potential therapies across four clinical trials, including Avexatide for post-bariatric hypoglycemia (PBH), AMX-thirty five for Wolfram syndrome and progressive supranuclear palsy (PSP), and AMX-one hundred fourteen for ALS [7][8] - Avexatide has shown promise in treating PBH, with a pivotal Phase III trial (Lucidity) initiated, and the first participant dosed [10][18] - AMX-thirty five is being evaluated in two indications, with positive Phase II data reported for Wolfram syndrome and ongoing trials for PSP [12][14] Market Data and Key Metrics Changes - There are approximately 160,000 people in the U.S. living with PBH, a condition with no approved treatment options [9][19] - The American Society for Metabolic and Bariatric Surgery reported approximately 270,000 new bariatric surgery procedures in 2023, indicating a stable market for potential PBH patients [20] Company Strategy and Development Direction - The company aims to execute across its clinical programs, focusing on diseases with high unmet needs [28] - The anticipated commercial launch of Avexatide is planned for 2027, contingent on successful trial outcomes [10] - The company is preparing for potential market entry and is focused on educating healthcare providers and patients about PBH [34][66] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving clinical milestones through the end of 2026, supported by a strong cash position [23][29] - The company is optimistic about the potential of its therapies, particularly Avexatide, given the high unmet need in PBH [84] - Management highlighted the importance of education and access for patients suffering from PBH, emphasizing the need for awareness in the medical community [34][66] Other Important Information - The company plans to present week 48 data from the HELIOS trial in Wolfram syndrome and expects to share unblinded Phase 2b data from the ORION trial in PSP in the third quarter [28] - The company is also preparing for early cohort data from the Phase I LUMINA trial of AMX-one hundred fourteen in ALS by the end of the year [28] Q&A Session Summary Question: Will a large patient education campaign be required for Avexatide in PBH? - Management acknowledged the need for education due to the rarity of treatments for PBH and the importance of informing both medical professionals and patients about the condition and potential treatment options [31][34] Question: What is the expected efficacy bogey on the PSP rating scale? - Management indicated that the study has 80% power to detect a 30% effect on the PSP rating scale, with multiple endpoints being considered for decision-making [35][37] Question: How many of the 160,000 PBH patients are seeking treatment? - Management clarified that while 160,000 represent those with persistent hypoglycemia, a larger group of 500,000 to 1 million may experience hypoglycemia post-bariatric surgery [44][46] Question: What are the remaining questions with the FDA on trial design? - Management stated that the week 48 data will inform the Phase III program, but specific details of discussions with the FDA were not disclosed [53][56] Question: Will there be subgroup analysis within the Avexatide study? - Management confirmed that the study is focused on a population experiencing frequent hypoglycemic events, and they do not anticipate step therapy restrictions due to the lack of approved therapies for PBH [61][62] Question: What gives confidence that GLP-one antagonists like Avexatide won't cause safety issues? - Management highlighted the good safety profile observed in both non-clinical and clinical data for Avexatide, noting that it is a competitive antagonist rather than a full agonist [69][71] Question: How does the company compare Avexatide to other drugs in the space? - Management emphasized that Avexatide is in Phase III with breakthrough therapy designation, and they believe it has a strong profile compared to earlier-stage programs [82][84]